Mablink Bioscience, a biotechnology company that focuses on advancing next-generation antibody-drug conjugates through its proprietary PSARLink™ platform, has announced its acquisition by Eli Lilly and Company.

Vaxcyte, Inc, has announced that the U.S. Food and Drug Administration has granted approval for the company's Investigational New Drug application for VAX-31, a 31-valent pneumococcal conjugate vaccine

Bolt Biotherapeutics has initiated its first-in-human Phase 1/2 clinical trial by dosing the inaugural patient with BDC-3042, a monoclonal antibody designed to repolarize tumor-associated macrophages (TAMs) for the purpose of combating cancer

SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, has recently entered into a license and option agreement with Synaffix B.V., a subsidiary of Lonza, to develop next-generation antibody-drug

Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company

Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has

AGC Biologics , a leading global biopharmaceutical contract developer and manufacturer (CDMO), today announced the completion of facility expansion for its new plasmid DNA (pDNA)

Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has commenced enrollment in the Phase 2

Lucy Therapeutics (LucyTx) has obtained additional funding from the International Rett Syndrome Foundation (IRSF) to support innovative treatments for individuals, both children and adults, grappling with Rett syndrome. This funding will also contribute to the expansion of LucyTx's pioneering treatment platform.

Eurofins CDMO Alphora Inc. announces that it has received its Health Canada Cannabis Drug License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario operations in September 2023. This compliments the Institutional Research License obtained through Health Canada in June 2021 for its Mississauga development site and a Standard Processing License obtained for the Oakville, Ontario manufacturing operation in May 2022.